UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 43

Sortiert nach

Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models

PharmacoEconomics, 2018-12, Vol.36 (12), p.1421-1426

2018

Volltextzugriff (PDF)

Frequentist and Bayesian meta‐regression of health state utilities for multiple myeloma incorporating systematic review and analysis of individual patient data

Health economics, 2019-05, Vol.28 (5), p.653-665

2019

Volltextzugriff (PDF)

The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK

PloS one, 2015-12, Vol.10 (12), p.e0145524

2015

Volltextzugriff (PDF)

Incorporating Prior Beliefs Into Meta-Analyses of Health-State Utility Values Using the Bayesian Power Prior

Value in health, 2023-09, Vol.26 (9), p.1389-1397

Hatswell, Anthony J.

2023

Volltextzugriff (PDF)

Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials

Health and quality of life outcomes, 2019-11, Vol.17 (1), p.171-171, Article 171

2019

Volltextzugriff (PDF)

Migraine day frequency in migraine prevention: longitudinal modelling approaches

BMC medical research methodology, 2019-01, Vol.19 (1), p.20-20, Article 20

2019

Volltextzugriff (PDF)

Carers’ Health-Related Quality of Life in Global Health Technology Assessment: Guidance, Case Studies and Recommendations

PharmacoEconomics, 2022-09, Vol.40 (9), p.837-850

2022

Volltextzugriff (PDF)

Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014

BMJ open, 2016-06, Vol.6 (6), p.e011666-e011666

2016

Volltextzugriff (PDF)

The validation of published utility mapping algorithms: An example of EORTC QLQ-C30 and EQ-5D in non-small cell lung cancer

Health economics review, 2020-04, Vol.10 (10), p.1-10, Article 10

2020

Volltextzugriff (PDF)

The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight

Value in health, 2016-12, Vol.19 (8), p.1055-1058

2016

Volltextzugriff (PDF)

The Cost-Effectiveness of Pixantrone for Third-/Fourth-Line Treatment of Aggressive Non-Hodgkin’s Lymphoma

Clinical therapeutics, 2016-03, Vol.38 (3), p.503-515

2016

Volltextzugriff (PDF)

Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia

Cost effectiveness and resource allocation, 2017-05, Vol.15 (1), p.8-8, Article 8

2017

Volltextzugriff (PDF)

New Cancer Drugs Fund solves the wrong problem

BMJ (Online), 2016-10, Vol.355, p.i5619

Hatswell, Anthony J

2016

Volltextzugriff (PDF)

Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma

Blood, 2022-08, Vol.140 (8), p.851-860

2022

Volltextzugriff (PDF)

Cost Effectiveness of Characterised Chondrocyte Implantation for Treatment of Cartilage Defects of the Knee in the UK

PharmacoEconomics, 2016-11, Vol.34 (11), p.1145-1159

2016

Volltextzugriff (PDF)

Real-world evidence use in assessments of cancer drugs by NICE

International journal of technology assessment in health care, 2020-08, Vol.36 (4), p.388-394

2020

Volltextzugriff (PDF)

Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death

Health and quality of life outcomes, 2014-09, Vol.12 (1), p.140-140, Article 140

2014

Volltextzugriff (PDF)

Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy

PharmacoEconomics, 2017-02, Vol.35 (2), p.163-176

2017

Volltextzugriff (PDF)

Learnings for Health Economics from the Early Stages of the COVID-19 Pandemic

PharmacoEconomics - open, 2020-06, Vol.4 (2), p.203-205

Hatswell, Anthony J.

2020

Volltextzugriff (PDF)

Creating historical controls using data from a previous line of treatment – Two non-standard approaches

Statistical methods in medical research, 2020-06, Vol.29 (6), p.1563-1572

2020

Volltextzugriff (PDF)

Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling

PharmacoEconomics, 2017-08, Vol.35 (8), p.755-757

2017

Volltextzugriff (PDF)

Approaches to Selecting “Time Zero” in External Control Arms with Multiple Potential Entry Points: A Simulation Study of 8 Approaches

Medical decision making, 2022-10, Vol.42 (7), p.893-905

2022

Volltextzugriff (PDF)

Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data

Clinical nephrology, 2022-05, Vol.97 (5), p.261

2022

Volltextzugriff (PDF)

Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer

PharmacoEconomics, 2024-01, Vol.42 (1), p.109-116

2024

Volltextzugriff (PDF)

Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal

PharmacoEconomics, 2020-12, Vol.38 (12), p.1309-1318

2020

Volltextzugriff (PDF)

1 – 25 von 43

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(43)
Mit Volltextzugriff
(40)

Publikationsform

Artikel
(43)

Sprache

Englisch
(43)
Japanisch
(2)

Erscheinungsjahr

n.n

Thema

Science & Technology
(36)
Life Sciences & Biomedicine
(35)
Health Care Sciences & Services
(25)
Humans
(22)
Health Policy & Services
(20)
Economics
(17)
Business & Economics
(16)
Social Sciences
(16)
Medicine
(15)
Medicine & Public Health
(15)
Health Economics
(13)
Pharmacoeconomics And Health Outcomes
(13)
Cost Analysis
(12)
Patients
(12)
Quality Of Life
(12)
Clinical Trials
(11)
Public Health
(11)
Health Technology Assessment
(10)
Pharmacology & Pharmacy
(10)
Health Administration
(9)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Probabilistic Sensitivity Analysis in Cost-Effectiveness Models: Determining Model Convergence in Cohort Models

Frequentist and Bayesian meta‐regression of health state utilities for multiple myeloma incorporating systematic review and analysis of individual patient data

The Predicted Impact of Ipilimumab Usage on Survival in Previously Treated Advanced or Metastatic Melanoma in the UK

Incorporating Prior Beliefs Into Meta-Analyses of Health-State Utility Values Using the Bayesian Power Prior

Longitudinal assessment of utilities in patients with migraine: an analysis of erenumab randomized controlled trials

Migraine day frequency in migraine prevention: longitudinal modelling approaches

Carers’ Health-Related Quality of Life in Global Health Technology Assessment: Guidance, Case Studies and Recommendations

Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014

The validation of published utility mapping algorithms: An example of EORTC QLQ-C30 and EQ-5D in non-small cell lung cancer

The Cost of Costing Treatments Incorrectly: Errors in the Application of Drug Prices in Economic Evaluation Due to Failing to Account for the Distribution of Patient Weight

The Cost-Effectiveness of Pixantrone for Third-/Fourth-Line Treatment of Aggressive Non-Hodgkin’s Lymphoma

Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia

New Cancer Drugs Fund solves the wrong problem

Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma

Cost Effectiveness of Characterised Chondrocyte Implantation for Treatment of Cartilage Defects of the Knee in the UK

Real-world evidence use in assessments of cancer drugs by NICE

Patient-reported utilities in advanced or metastatic melanoma, including analysis of utilities by time to death

Economic Evaluations of Pharmaceuticals Granted a Marketing Authorisation Without the Results of Randomised Trials: A Systematic Review and Taxonomy

Learnings for Health Economics from the Early Stages of the COVID-19 Pandemic

Creating historical controls using data from a previous line of treatment – Two non-standard approaches

Sharing is Caring: The Case for Company-Level Collaboration in Pharmacoeconomic Modelling

Approaches to Selecting “Time Zero” in External Control Arms with Multiple Potential Entry Points: A Simulation Study of 8 Approaches

Comparative efficacy of ravulizumab and eculizumab in the treatment of atypical hemolytic uremic syndrome: An indirect comparison using clinical trial data

Modelling Health State Utilities as a Transformation of Time to Death in Patients with Non-Small Cell Lung Cancer

Voretigene Neparvovec for Treating Inherited Retinal Dystrophies Caused by RPE65 Gene Mutations: An Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal

Suchergebnisse filtern